Pharmacy Medical News about Pain Therapeutics Genes

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Genetic modulation of the pharmacological treatment of pain
Pharmacology & Therapeutics, 11/06/09

Lotsch J et al. – Inadequately treated acute and chronic pain remains a major cause of suffering and dissatisfaction in pain therapy. A cause for the variable success of pharmacologic pain therapy is the different genetic disposition of patients to develop pain or to respond to analgesics. The patient's phenotype may be regarded as the result of synergistic or antagonistic effects of several genetic variants concomitantly present in an individual. Variants modulate the risk of developing painful disease or its clinical course (e.g., migraine, fibromyalgia, low back pain). Other variants modulate the perception of pain (e.g., OPRM1 or GCH1 variants conferring modest pain protection by increasing the tone of the endogenous opioid system or decreasing nitric oxide formation). Other polymorphisms alter pharmacokinetic mechanisms controlling the local availability of active analgesic molecules at their effector sites (e.g., decreased CYP2D6 related prodrug activation of codeine to morphine). In addition, genetic variants may alter pharmacodynamic mechanisms controlling the interaction of the analgesic molecules with their target structures.

<< Previous
Update on the Management of Pain in Arthritis and the Use of...

Next >>
Analysis of the impact and burden of illness of adult chronic ITP...

Elevated Saliva Calcitonin Gene-Related Peptide Levels During Acute Migraine Predict Therapeutic Response to Rizatriptan
Headache: The Journal of Head and Face Pain, 10/15/09 Relevance Score: 79%

Developments in the scientific and clinical understanding of fibromyalgia
Arthritis Research & Therapy, 10/16/09 Relevance Score: 78%

A Clinical Trial of Gene Therapy for Chronic Pain
Pain Medicine, 10/14/09 Relevance Score: 70%

The pharmacological treatment of neuropathic pain
European Journal of Pain, 11/12/09 Relevance Score: 69%

Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans
Pain, 10/06/09 Relevance Score: 69%